OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden
hours per response...0.5

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935
or Section 30(h) of the Investment Company Act of 1940

o	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Name and Address of Reporting
Person*

Issuer Name and Ticker or Trading
Symbol

I.R.S. Identification Number of Reporting
Person, if an entity (Voluntary)

Metz, John S.

(Last) (First) (Middle)

Bio-Plexus, Inc. Symbol: "BPXS

c/o Bio-Plexus, Inc.
129 Reservoir Road

(Street)

Statement for Month/Day/Year

If Amendment, Date of Original (Month/Day/Year)

11/2002

Relationship of Reporting Person(s)
to Issuer (Check All Applicable)

Individual or Joint/Group Filing
(Check Applicable Line)

Vernon, CT, 06066

(City) (State) (Zip)

Director

10% Owner

Form Filed by One Reporting Person

Officer (give title below)

Form Filed by More than One Reporting Person

Other (specify below)

President and Chief Executive Officer

Reminder:		Report on a separate line for each class of securities beneficially owned directly or indirectly.

*		If the form is filed by more than one reporting person, see instruction 4(b)(v).

Table I — Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Title of Security
(Instr. 3)

Transaction
Date
(Month/Day/Year)

2A.

Deemed Execution
Date, if any
(Month/Day/Year)

Transaction
Code
(Instr. 8)

Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5)

Amount of Sec-
urities Beneficially
Owned Following
Reported Trans-
action(s)
(Instr. 3 and 4)

Ownership
Form:
Direct (D) or
Indirect (I)
(Instr. 4)

Nature of
Indirect
Beneficial
Ownership
(Instr. 4)

Code

Amount

(A)
or
(D)

Price

Common Stock, par value $.001

1,000 (1)

Common Stock, par value $.001

50,000(2)

Common Stock, par value $.001

6/18/02

65,360

$33,333

65,360

Common Stock, par value $.001

11/12/02

115,602

$76,360.91

(115,602)(2)

Page 2

Table II — Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Title of Derivative
Security
(Instr. 3)

Conversion or Exercise
Price of Derivative
Security

Transaction
Date
(Month/Day/Year)

3A.

Deemed Execution
Date, if any
(Month/Day/Year)

Transaction
Code
(Instr. 8)

Number of Derivative Securities
Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)

Code

(A)

(D)

Warrants to Purchase Common Stock

$1.00

6/19/02

8,333

Stock Options (4)

$2.283

7/19/01

A 4

150,000

Warrants to Purchase Common Stock

11/12/02

8,333

Page 3

Table II — Derivative Securities Acquired, Disposed of, or Beneficially Owned — Continued
(e.g., puts, calls, warrants, options, convertible securities)

Date Exercisable and
Expiration Date
(Month/Day/Year)

Title and Amount
of Underlying Securities
(Instr. 3 and 4)

Price of Derivative
Security
(Instr. 5)

Number of Derivative Securities
Beneficially Owned Following
Reported Transaction(s)
(Instr. 4)

10.

Ownership Form of
Derivative Security:
Direct (D) or
Indirect (I)
(Instr. 4)

11.

Nature of
Indirect
Beneficial
Ownership
(Instr. 4)

Date
Exercisable

Expiration
Date

Title

Amount or
Number of
Shares

6/18/02

12/18/04

Common Stock

8,333

(3)

8,333

(4)

7/19/11

Common Stock

150,000

Common Stock

8,333

(3)

(8,333)

Explanation of Responses:

(1) A total of 10,000 shares were reported on the Reporting Person's Form 4 filed on September 6, 2000. During 2001, the Issuer affected a reverse stock split whereas each ten shares of Issuer common stock were converted into one share of Issuer common stock.

(2) Consists of restricted stock issued pursuant to Issuer's 2001 Stock Incentive Plan. Represents shares of Restricted Stock having an initial fair market value of $2.283 per share, as determined by the Issuer's Board of Directors and by a new investment in the Company at the issuance date. Vesting occurred on May 24, 2002 upon a change of control. On November 12, 2002, these shares were sold to ICU Medical, Inc. at a per price share of $0.66.

(3) Derivative Securities were issued as part of Units each consisting of Subordinated 7% Non-Convertible Promissory Notes and Warrants to purchase 50,000 shares of Common Stock. The reporting person purchased 0.16 Unit for a purchase price of $16,667. On November 12, 2002, the notes were sold for $16,667 and the warrants were sold for $-0- to ICU Medical, Inc.

(4) Vested on change of control on May 24, 2002.

/S/John S. Metz		November 12, 2002
**Signature of Reporting Person		Date

**		Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note:		File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Page 4

BIO PLEXUS INC 4